Alibaba Health Information Technology Stock Advances 4.1% in Hong Kong
DouBao, known for its aggressive cash-burning strategy, has started charging fees, marking the 'commercialization epoch year' for China's large-scale AI models.
DouBao, with 345 million monthly active users and an average daily consumption of 120 trillion tokens, is shifting its computing power costs to heavy users. According to Morgan Stanley estimates, under an optimistic scenario, DouBao’s annual subscription revenue could reach 1.5 billion US dollars. As the most aggressive subsidizer in China’s consumer-level AI sector, DouBao’s move sends a significant signal: the cultivation phase of Chinese consumers’ AI usage habits has largely been completed, and the industry is transitioning from user subsidies to commercial sustainability.
Alibaba Health Information Technology Stock Slides 1.1% in Hong Kong
Morgan Stanley has lowered its target price for Ali Health (00241.HK) to HKD 4.2 and maintained a 'Reduce' rating.
Morgan Stanley issued a research report updating its risk-return assessment for Ali Health (00241.HK). It maintained its revenue forecasts for the fiscal years 2026 to 2028 largely unchanged, expecting growth of 12%, 10%, and 9%, respectively. However, due to increased R&D expenditures and a downward revision in gross margin assumptions (influenced by the faster growth of self-operated business compared to third-party platform business), the firm lowered its earnings per share forecasts for Ali Health by 13.8%, 14.7%, and 11.9% for the fiscal years 2026 to 2028. Adjusted net profit is projected to grow by 19%, 18%, and 18% during the same period. Morgan Stanley believes that Ali Health's valuation remains relatively less attractive compared to its peers.
Alibaba Health Information Technology Stock Climbs 2.3% in Hong Kong
ALI HEALTH: DATE OF BOARD MEETING